Yescarta denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for yescarta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Yescarta: Non-Formulary

Yescarta (axicabtagene ciloleucel) is a CAR-T cell therapy administered in a certified inpatient or outpatient hospital setting — it is not a retail pharmacy drug. UHC's formulary structure for specialty biologics and cell therapies differs from its retail drug formulary, and a "non-formulary" denial for Yescarta typically means one of the following: the drug is not included on the specific plan's specialty tier, the claim was processed under the pharmacy benefit rather than the medical benefit (where CAR-T is almost always covered), or the specific product was not on the plan's preferred CAR-T list at the time of the request.

## Why This Is Appealable

For an FDA-approved therapy like Yescarta with no generic or biosimilar equivalent, non-formulary denials are subject to a formulary exception process. Under ACA rules, plans must provide exceptions to formulary restrictions when a covered drug is not clinically appropriate for a patient or when the formulary alternative has already failed. Because there is no therapeutic equivalent to Yescarta for its approved indications, a formulary exception request is well-supported. Additionally, if Yescarta should be billed under the medical benefit rather than the pharmacy benefit, a billing correction may resolve the denial entirely.

## Federal Appeal Framework

• Formulary exception request: This is often a separate, faster track than a standard appeal. Submit the exception request alongside or before the internal appeal.
• Internal appeal: File under ACA §2719 / ERISA §503 within the timeframe on the denial notice. Expedited review is available for urgent oncology situations.
• External review: Available after the internal process is exhausted, within four months of the final internal denial.

## Documentation to Collect

1. Benefit verification — confirm with UHC whether Yescarta should be adjudicated under the medical benefit (as a physician-administered drug) or the pharmacy benefit. Request this clarification in writing. 2. Formulary exception form — obtain UHC's formulary exception form and have your oncologist complete it. 3. No-equivalent documentation — your oncologist should attest that no formulary alternative is clinically appropriate for your specific diagnosis and disease history. 4. Diagnosis and prior-therapy records — same documentation as for a medical necessity appeal: pathology, staging, and prior-treatment history. 5. Prescriber letter — explaining that Yescarta is the appropriate therapy for your specific indication and that no formulary alternative exists for this use.

## Criteria-Mapping Structure

For the formulary exception, create a table showing: the formulary alternative UHC would prefer (if any was named), the clinical reason it is not appropriate for you, and the documentation that supports each reason. If no alternative was named, state that explicitly and document that no equivalent product is FDA-approved for your indication.